1
=
-
IQVIA Holdings Inc.
As of May 21, 2026 at 10:37 UTC
Chart
About IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Market Statistics
Trading Metrics
How to Buy IQV
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy IQV
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesDark Horse Consulting Group and KunTuo Medical Research and Development have signed a Memorandum of Understanding to establish a strategic collaboration providing biotherapeutics developers with an integrated pathway for conducting clinical trials in China. The partnership combines DHCG's regulatory and consulting expertise with KunTuo's clinical research capabilities and resources across China, aiming to accelerate cell and gene therapy development and reduce delays in trial initiation.
Following a market rally driven by US-Iran peace deal hopes and strong tech earnings, eight underperforming US stocks are identified as having significant upside potential of 25-85%. While the S&P 500 and NASDAQ reached record highs, certain stocks have fallen 10-20% over two weeks despite strong fundamentals. IQVIA and Sonoco are highlighted as examples of beaten-down stocks trading well below fair value estimates with analyst upside targets of 20-97%.
Eli Lilly's stock dropped nearly 4% on Friday following disappointing early prescription data for its newly FDA-approved weight-loss pill Foundayo. The drug recorded only 3,707 prescriptions in its second week, significantly trailing competitor Novo Nordisk's Wegovy pill which had 18,410 prescriptions in its second week. While Lilly cautioned that weekly data may not be comprehensive, the sluggish start raises concerns despite the company's strong overall portfolio.
The clinical trial management system (CTMS) market is experiencing significant growth, expanding from $2.25 billion in 2025 to $2.54 billion in 2026 at a 13.1% CAGR, with projections reaching $4.2 billion by 2030. Growth is driven by increasing global clinical trials, adoption of cloud-based platforms, AI-powered analytics, and decentralized trial models. Key players are making strategic moves including platform launches and acquisitions to enhance technological capabilities.
The AI clinical trial protocol feasibility tool market is experiencing rapid expansion, growing from $0.83 billion in 2025 to $1.06 billion in 2026 with a 27.3% CAGR. The market is projected to reach $2.76 billion by 2030, driven by increasing protocol complexity, precision medicine focus, decentralized trial designs, and AI-enabled protocol optimization. Key players include IQVIA Holdings, SAS Institute, Veeva Systems, and Tempus AI, with North America leading and Asia-Pacific emerging as the fastest-growing region.
